Cell Therapy News Volume 25.32 | Oct 21 2024

    0
    64








    2024-10-21 | CTN 25.32


    Cell Therapy News by STEMCELL Technologies
    Vol. 25.32 – 21 October, 2024
    TOP STORY

    AAV Gene Therapy for Duchenne Muscular Dystrophy: The EMBARK Phase III Randomized Trial

    A Phase III EMBARK study aimed to assess the efficacy and safety of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy was conducted.
    [Nature Medicine]

    Full ArticlePress Release
    PUBLICATIONSListed by the impact factor of the journal

    Targeting Overexpressed Antigens in Glioblastoma via CAR T Cells with Computationally Designed High-Affinity Protein Binders

    Investigators reported the development and therapeutic performance of CAR constructs leveraging protein binders computationally designed de novo to have high affinity for the epidermal growth factor receptor or the tumor-associated antigen CD276, which were overexpressed in glioblastoma.
    [Nature Biomedical Engineering]

    Abstract

    Single-Cell Analysis of the Multiple Myeloma Microenvironment after Gamma-Secretase Inhibition and CAR T Cell Therapy

    Leveraging a Phase I clinical trial of the gamma-secretase inhibitor, crenigacestat, with anti-BCMA CAR T cells, researchers utilized single-nuclei RNA sequencing and Assay for Transposase-Accessible Chromatin sequencing to characterize the effects of gamma-secretase inhibitor on the tumor microenvironment.
    [Blood]

    Abstract

    Visualization of Type IV-A1 CRISPR-Mediated Repression of Gene Expression and Plasmid Replication

    Targeting of reporter genes revealed extended interference in P. oleovorans and Escherichia coli cells producing recombinant CRISPR ribonucleoprotein complexes.
    [Nucleic Acids Research]

    Full Article
    Graphical Abstract

    Transient CAR T Cells with Specificity to Oncofetal Glycosaminoglycans in Solid Tumors

    The authors reported the design and functionality of transient CAR T cells with selectivity to oncofetal chondroitin sulfate.
    [EMBO Molecular Medicine]

    Full ArticleGraphical Abstract

    Gene Therapy for Fat-1 Prevents Obesity-Induced Metabolic Dysfunction, Cellular Senescence, and Osteoarthritis

    Mice were placed on an ω-6-rich high-fat diet or a lean control diet and underwent destabilization of the medial meniscus to induce osteoarthritis. Obesity and joint injury significantly increased cellular senescence in subcutaneous and visceral fat as well as joint tissues such as synovium and cartilage.
    [Proceedings of The National Academy of Sciences of The United States of America]

    Abstract

    NSGS Mice Humanized with Cord Blood Mononuclear Cells Show Sustained and Functional Myeloid–Lymphoid Representation with Limited Graft-Versus-Host Disease

    Researchers assessed the engraftment dynamics of various human immune cells over time and monitored the development of graft-versus-host disease in both models.
    [Journal For Immunotherapy of Cancer]

    AbstractPress Release

    Immune Effector Cell-Associated Enterocolitis Following Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma

    Investigators reported 14 cases of immune effector cell-associated enterocolitis following CAR-T therapy in multiple myeloma, with a 1.2% incidence overall.
    [Blood Cancer Journal]

    Full Article

    A Novel Mitochondrial Pyruvate Carrier Inhibitor Drives Stem Cell-Like Memory CAR T Cell Generation and Enhances Antitumor Efficacy

    Investigators used a novel mitochondrial pyruvate carrier inhibitor, MITO-66, which robustly induced a stem cell-like memory phenotype in CD19-CAR T cells generated from healthy donors and patients with relapsed/refractory B cell malignancies.
    [Molecular Therapy Oncology]

    AbstractGraphical Abstract
    Image of man completing the on-demand CFU assay course on his laptop.
    REVIEWS

    Cell Therapy for Neurological Disorders

    With all the remarkable new approaches to treat neurological disorders, the authors take a critical look at the state of current clinical trials and how challenges may be overcome with the evolving technology and innovation occurring in the stem cell field.
    [Nature Medicine]

    Abstract

    Sequencing of Cellular Therapy and Bispecific Antibodies for the Management of Diffuse Large B Cell Lymphoma

    The development and advancement of these novel therapies raise questions regarding the ongoing role of HSCT in the management of R/R DLBCL and the best sequence of cellular and bispecific therapies to optimize patients’ outcomes.
    [Haematologica]

    Full Article

    Roctavian Gene Therapy for Hemophilia A

    Scientists focus on the clinical development of Roctavian for which the collective clinical trials represent the largest body of work thus far available for any licensed adeno-associated virus product.
    [Blood Advances]

    Full Article
    INDUSTRY AND POLICY NEWS

    US$225 Million Investment towards World-Class Research Institute

    Cancer Research UK has invested in an institute outside of London to accelerate advancement in personalized medicine and early detection, The University of Cambridge has announced it will open a new facility to deliver CAR-T cell therapies, enabling more treatments for patients.
    [Cancer Research UK (RegenMedNet)]

    Press Release

    New Lab to Open to Make Cutting-Edge CAR-T Cells in Cambridge

    A new state-of-the-art laboratory is set to open at Addenbrooke’s Hospital that will deliver ‘home-grown’ CAR-T cells to help improve treatment for blood cancers.
    [NHS]

    Press Release
    FEATURED EVENT

    Antibody Engineering with Novel Technologies

    November 20, 2024
    Online

    > See All Events

    JOB OPPORTUNITIES

    Professor – Biomedical Engineering

    University of Wisconsin Madison – Madison, Wisconsin, United States

    Senior Scientist – Cellular Therapy Safety Testing

    Bristol-Myers Squibb – Seattle, Washington, United States

    Research Assistant – Cell Therapy Research

    Baylor College of Medicine – Houston, Texas, United States

    Senior Scientist – Cellular Therapy Safety Testing

    Bristol-Myers Squibb – Seattle, Washington, United States

    Research Associate – Self-Renewing Macrophages in Tumor Biology

    TU Dresden – Dresden, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2